Lung cancer ranks among the most common cancers world-wide and is the first cancer-
related cause of death. The classification of lung cancer has evolved tremendously over the …

Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous
system (CNS) metastases. Current treatments for this subgroup of patients with advanced …

The Kirsten rat sarcoma viral oncoprotein homolog (KRAS) is currently a primary focus of
oncologists and translational scientists, driven by exciting results with KRAS-targeted …

Background Sotorasib showed a significant improvement of progression free survival (PFS),
safety and quality of life over docetaxel in patients with KRASp. G12C–mutated advanced …

Among the most common molecular alterations detected in non-small-cell lung cancer
(NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS). KRAS …

Objectives Limited data are available on central nervous system (CNS) efficacy with
standard-of-care therapies for KRAS-mutated (KRASmut) advanced non-small cell lung …

Background In recent years, groundbreaking advancements in lung cancer research have
paved the way for innovative treatments directly targeting KRAS mutations, which have long …

RAS (rat sarcoma viral oncogene homolog) proteins were among the earliest identified
proteins that regulate cell growth, differentiation, and survival. The seminal work of Harvey …

KRAS mutation is the most frequent oncogenic driver in non-small cell lung cancer
(NSCLC), observed in up to 30% of patients with non-squamous NSCLC (1), with a higher …

The first-line therapy for patients with adenocarcinoma or squamous cell carcinoma is what's
already FDA approved such as those used in KEYNOTE-189 [NCT02578680], KEYNOTE …